Publications by authors named "I Andreadou"
Article Synopsis
- Cardiac amyloidosis involves the buildup of amyloid proteins in the heart, affecting its functioning and the prognosis of patients, with biomarkers being crucial for assessment.
- Treatment options are limited as traditional heart failure therapies are often ineffective, highlighting the need for targeted strategies to manage amyloid deposition.
- The mechanisms behind organ damage in cardiac amyloidosis are complex and involve factors like oxidative stress and inflammation, which are being investigated for potential therapeutic strategies.
Cardioprotective potential of oleuropein, hydroxytyrosol, oleocanthal and their combination: Unravelling complementary effects on acute myocardial infarction and metabolic syndrome.
Redox Biol
October 2024
Clinical studies have previously established the role of olive products in cardiovascular disease (CVD) prevention, whilst the identification of the responsible constituents for the beneficial effects is still pending. We sought to assess and compare the cardioprotective potential of oleuropein (OL), hydroxytyrosol (HT), oleocanthal (OC) and oleanolic Acid (OA), regarding Ischemia/Reperfusion Injury (IRI) and CVD risk factors alleviation. The scope of the study was to design a potent and safe combinatorial therapy for high-cardiovascular-risk patients on a bench-to-bedside approach.
View Article and Find Full Text PDFEndothelial dysfunction often precedes the development of cardiovascular diseases, including heart failure. The cardioprotective benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) could be explained by their favorable impact on the endothelium. In this review, we summarize the current knowledge on the direct in vitro effects of SGLT2is on endothelial cells, as well as the systematic observations in preclinical models.
View Article and Find Full Text PDFHypertension poses a significant global health burden and is associated with cardiovascular morbidity. Chios mastic gum (CMG), derived from var. , shows potential as a phytotherapeutic agent, due to its multifaceted beneficial effects.
View Article and Find Full Text PDFArticle Synopsis
- Cancer therapy-related cardiovascular adverse events (CAEs), especially with drugs like Carfilzomib (Cfz), are a growing concern in patients who also have comorbidities like cardiometabolic syndrome (CMS) and heart failure with reduced ejection fraction (HFrEF).
- In experiments with mice models, it was found that Cfz did not worsen LV dysfunction in CMS but caused metabolic issues; co-administration of metformin and atorvastatin helped protect against these cardiac complications.
- The study concludes that while CMS and HFrEF can worsen Cfz-related CAEs through metabolic and inflammatory mechanisms, metformin shows potential as a protective agent in mitigating these adverse effects.